New reps make more than reps presently employed

Quote


















anonymous said:
Again, where did the OP talk about discrimination or lawsuits being filed? All he said was he left a good gig to come here and is concerned. If things are true is it legal. You added assumptions and then started calling people names. After reading these posts and hearing you, I think this company is messed up. You are doing a bad job of damage control
Click to expand...

Lol! Damage control. Also, do you think that i or anyone else on here cares what you think about the company, especially if you’re basing it off of cafepharma. Lmao! The post literally asked if anyone had sued over it. By all means, if you find it messed up, then please leave this board.
 






anonymous said:
Lol! Damage control. Also, do you think that i or anyone else on here cares what you think about the company, especially if you’re basing it off of cafepharma. Lmao! The post literally asked if anyone had sued over it. By all means, if you find it messed up, then please leave this board.
Click to expand...

Lol! You tell people no to take this site seriously and ignore advice. So what do you do in the very same post? You give advice and tell them to leave. You are just upset because neurocrine is going to be brought by the end of summer
 


















anonymous said:
Lol! You tell people no to take this site seriously and ignore advice. So what do you do in the very same post? You give advice and tell them to leave. You are just upset because neurocrine is going to be brought by the end of summer
Click to expand...

Points from trying to distract from the fact that you were wrong in your claims that there was no mention of suing in the first post. Listen, if you don't come to nuerocrine based on what you read on cafepharma, then it is nothing but a benefit to the company. You do you, but don't come on here telling me that I'm wrong about what a post said when its literally a few posts above, moron.
 






anonymous said:
Points from trying to distract from the fact that you were wrong in your claims that there was no mention of suing in the first post. Listen, if you don't come to nuerocrine based on what you read on cafepharma, then it is nothing but a benefit to the company. You do you, but don't come on here telling me that I'm wrong about what a post said when its literally a few posts above, moron.
Click to expand...

We have read your posts kid. You are trying to hard to deflect and sound confident. Give it up already. Lol!
 




































anonymous said:
Just when I think you can’t get more pathetic, you do! Please, keep avoiding that you were wrong about the OP mentioning suing. Go ahead. It’s pretty entertaining, actually.
Click to expand...

you still on here deflecting? Move on already. It's been a couple of days now and you are still trying to get people to acknowledge you. I don't think anyone cares. Lol! You were wrong
 












anonymous said:
Yes, especially at THAT price!!! This nothing but a way to gauge the US healthcare system! And any rep, that sells this crap ist eagerly participating!!
Click to expand...

Explaining the Renewed Interest in Tardive Dyskinesia
Jeffrey A. Lieberman, MD

one cannot help but notice the resurgent interest in TD in the form of a striking increase in information, publications, and research that has coincided with the marketing of these new patented medications, and whatever their price point is.

These ...new drugs...have breathed new life into this area, but it is disproportionate to the magnitude of the clinical problem.
 






Ah impressive of you displaying your high level googling skills on here Homer. Posting shit on cafe pharma does not mean jack pal. Hop to it loser go try selling this shit can drug to your neuros loser.
 






anonymous said:
Explaining the Renewed Interest in Tardive Dyskinesia
Jeffrey A. Lieberman, MD

one cannot help but notice the resurgent interest in TD in the form of a striking increase in information, publications, and research that has coincided with the marketing of these new patented medications, and whatever their price point is.

These ...new drugs...have breathed new life into this area, but it is disproportionate to the magnitude of the clinical problem.
Click to expand...

True, but also remember many are well undertrained on how to diagnose TD and do proper AIMS assessments. For example, one of the reasons why Neurocrine lowered their forecast for Ingrezza and many financial forecasts lowered Neurocrine from buy to overweight is because many mental health professionals have issues with diagnosing TD. Many of these medical professionals cannot diagnose the difference between DIP, TD, Dsystonia, etc and other involuntary movement disorders according to their own personal studies. This information is available at ZACs. My point is and what other investors are wondering is how much is this disease of TD being recognized? for example look at how many people stay on Ingrezza medication. Half of patients on Ingrezza quick after six months and another 25% quit after a year. So, if you have a chronic condition of involutary movements due to TD you are not stopping medication unless it does not work. Which means healthcare professionals cant tell the difference between TD, Dystonia and Drug induced Parkinsons. That is until they try a VMAT2. If the patients condition improves, then you know its TD. If the patients condition does not improve, then it is something else. My point being, is TD really growing or is it that professionals cant tell the difference between other similar movement diseases/conditions. I am willing to bet half the people on Ingrezza should not have been Rx it and then fall off after a few months because their condition is Dystonia or DIP which is way more common then TD. Which is part of the reason why investors are thinking twice about investing in Neurocrine and why Neurocrine lowered their growth for Ingrezza even after doubling their sales force.
 






And there in lies the million dollar question? Why are we adding so many in headcount and increasing our overhead when this patient population is still relatively small. We can get patients started on medication, but when those patients DC the treatment within months, provider and patient retention creates a bigger issue than new starts. When those same providers that have tried it on their patients become frustrated with compliance it then become a viscous cycle and oh by the way, the sales goals keep going up.
 






Top Bottom
Back
Quote